{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-240858","form_type":"8-K","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2025-10-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.156397+00:00","generated_at":"2026-05-17T03:34:29.009288+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dianthus licenses DNTH212 from Leads Biolabs; $30M upfront, $962M potential milestones","bullets":["Up to $38M in upfront and near-term payments ($30M cash plus $8M milestone at Phase 1 start).","Additional up to $962M in development, regulatory, and sales-based milestones across five indications.","Tiered royalties from mid-single digits to low double-digit on ex-Greater China net sales.","Preliminary cash $555M as of Sep 30, 2025; pro forma $525M after $30M payment to Leads."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-240858","json":"https://secwatch.observer/filing/0001193125-25-240858.json","markdown":"https://secwatch.observer/filing/0001193125-25-240858.md","text":"https://secwatch.observer/filing/0001193125-25-240858.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312525240858/0001193125-25-240858-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312525240858/dnth-20251016.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:34:29.009288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}